ArticleMicrobiology spectrum2026
A novel
Tatsuro Hirayama, Natsume Kitahori, Mizuki Ishimine, NaNa Nakada, Yuya Ito, Naoki Iwanaga, Takahiro Takazono, Taiga Miyazaki, Koichi Izumikawa, Katsunori Yanagihara and 3 more
Abstract read
In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Tatsuro HirayamaDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0001-8554-3482 Natsume KitahoriDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mizuki IshimineDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
NaNa NakadaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Yuya ItoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Takahiro TakazonoDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Taiga MiyazakiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-0962-5758 Koichi IzumikawaDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Koichi MakimuraTeikyo University Institute of Medical Mycology, Teikyo University, Itabashi City, Tokyo, Japan.
Kazuhiro TsukamotoDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Funding
Japan Agency for Medical Research and Development JP26fk0108700Japan Society for the Promotion of Science 24K11656MSD Life Science Foundation, Public Interest Incorporated Foundation
6 · The paper itselfAbstract
Fosmanogepix (FMGX) is the prodrug of manogepix (MGX), which targets Gwt1, an inositol acyltransferase encoded by
Indexed as
Antifungal AgentsCandida aurisFungal ProteinsAmidinesAnimalsCandidiasisDrug Resistance, FungalMicrobial Sensitivity TestsMothsAmidinesAntifungal AgentsFungal ProteinsT-2307Candida aurisfosmanogepixGWT1manogepixTAC1B
Identifiers
PMID42678188
PMCPMC13688795
What OpenQuestion holds
Textmetadata
Read underepoch 390